Bausch + Lomb announces acquisition of AcuFocus
Click Here to Manage Email Alerts
KOLOA, Hawaii — Bausch + Lomb has announced that an affiliate of the company has acquired AcuFocus.
The announcement follows FDA approval of AcuFocus’ IC-8 Apthera small-aperture non-toric extended depth of focus IOL in July 2022.
The IC-8 Apthera is indicated for certain cataract patients with low amounts of corneal astigmatism who also wish to address presbyopia at the same time.
“Today’s acquisition of AcuFocus will allow us to further expand upon our IOL portfolio so we can help address the needs of surgeons and their patients with cataracts,” Anthony Wallace, vice president and general manager of Bausch + Lomb Surgical told Healio. “It is just one example of how we are continuously focused on identifying opportunities that help us deliver on our mission of helping patients see better so they can live better. We look forward to leveraging our broad network to help educate physicians about the benefits of the IC-8 Apthera IOL.”
The acquisition is pursuant to a merger transaction with the parent company of AcuFocus, according to a Bausch + Lomb press release; financial details were not included.
“Our mission at AcuFocus has been to develop and deliver breakthrough small aperture technology to help patients achieve their best personal vision; today, Bausch + Lomb is making that mission a reality,” Yari Mitchell, chief business development officer for AcuFocus, told Healio. “We are delighted to work with them to launch the IC-8 Apthera IOL in the U.S. and throughout their vast global network.”
Editor's note: On Jan. 17, 2023, this article was updated to include comments from Anthony Wallace.